SMMT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SMMT is not a strong buy right now for a Beginner-focused, long-term investor with $50,000-$100,000 to deploy. The stock has pre-market strength, but the broader technical trend is still weak, analyst sentiment has recently become more cautious, and the latest catalyst set is still tied to high-risk clinical readouts. For an impatient investor who does not want to wait for a better entry, this is still not a compelling long-term buy today.
Technically, SMMT is mixed to bearish. MACD histogram is negative at -0.0188, though contracting, which suggests downside momentum is easing but not yet reversed. RSI_6 is near neutral at 50.043, so there is no strong momentum confirmation. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, indicating the stock remains in a weaker trend despite the pre-market bounce to 17.86 (+2.58%). Price is sitting near the pivot at 17.141, with immediate resistance at 18.386 and 19.156 and support at 15.896 and 15.126. Overall, the chart does not yet support a confident long-term entry.
["Pre-market price is up 2.58%, showing near-term buying interest.", "Stifel maintains a Buy and $45 target, citing ivonescimab as a potentially category-leading PD-1xVEGF bispecific.", "Guggenheim remains constructive and expects investors to be positively surprised by ASCO plenary selection for Akeso's HARMONi-6 data.", "Similar-candlestick trend data suggests a possible 6.29% gain over the next month.", "Options positioning leans bullish with put-call ratios below 1.0."]
["H.C. Wainwright cut its target to $23 from $30, noting the lack of a stronger interim signal in HARMONi-3 increases risk for the final readout in H2 2026.", "Piper Sandler cut its target to $16 from $17 and kept Neutral, pointing to investor concerns after the Q1 update and interim analysis review.", "Clear Street lowered its target to $31 from $32 and flagged the non-disclosure of interim PFS as a negative interpretation.", "Jefferies downgraded the stock to Hold and sharply cut its target to $15 from $42, highlighting multiple catalyst risks.", "Technical trend remains bearish with SMA_200 > SMA_20 > SMA_5 and negative MACD.", "News flow in the provided data is not supportive for SMMT and the latest financial snapshot is unavailable."]
The latest quarter financial snapshot was not available due to an error, so there is no usable revenue or earnings trend to assess from the provided data. Based on the information given, the stock remains fundamentally driven by clinical trial progress rather than current quarterly financial performance. For a long-term beginner investor, the absence of clear financial growth data makes this a less suitable immediate buy.
Analyst sentiment has weakened recently. Earlier in April, Stifel and Guggenheim were bullish with Buy ratings and high price targets, but the tone turned more cautious in late April and early May. Clear Street cut its target slightly but stayed Buy, while Piper Sandler moved to Neutral and Jefferies downgraded to Hold with a sharp target cut. H.C. Wainwright also lowered its target from $30 to $23, still maintaining Buy but explicitly raising concern about HARMONi-3 risk. Wall Street is split, but the recent trend is clearly toward lower targets and more caution, which is a downside signal for a long-term entry today.
